Product Description: Trabikibart (CSL311), a βc-specific, fully human monoclonal antibody, binds to a unique epitope that is specific to the cytokine-binding site of the human βc receptor. Trabikibart has picomolar binding affinity for the human βc receptor. Trabikibart is a potent inhibitor of the combined effects of IL-3, GM-CSF and IL-5 on the survival of eosinophils. Trabikibart has the potential for chronic inflammatory diseases research[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Con Panousis, et al. CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors. MAbs. 2016;8(3):436-53.
CAS Number: 2643974-98-3
Molecular Weight: N/A
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Others
English
Deutsch
